JAK2 and cardiac hypertrophy: In summary, our study provides evidence that PM protects against pathological cardiac hypertrophy by inhibiting levels of the STAT3 phosphorylation and nuclear translocation to suppress the activation of JAK2/STAT3 signalling pathway (Figure 6).